Addendum
Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) – Addendum to Commission A22-80
Report documents
-
Addendum
Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) – Addendum to Commission A22-80
Dossier assessment
Indication:
Patients with unresectable or metastatic HER2-positive breast cancer who have previously received one HER2-targeted therapy
Result of dossier assessment:
After addendum now:
- Patients < 65 years: hint of major added benefit
- Patients ≥ 65 years: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-02-02 A G-BA decision was published.
Project details
- Project no.
- A22-126
- Commission
- Commission awarded on 06.12.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed